Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galidesivir for Yellow Fever or COVID-19
NCT03891420Phase 1Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in yellow fever and coronavirus disease 2019 (COVID-19) comparing Galidesivir with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 56 days, Change in Laboratory Parameters at 56 days and 1 more. Started Apr 2020; status: terminated.
02
Drugs
galidesivir
03
Conditions
yellow fevercoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT03891420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891420.